A long-lasting universal flu vaccine
For decades, researchers have been doggedly pursuing a universal flu vaccine--one that would protect against the evolving influenza virus for years rather than just a single season--with little success. The bug mutates so quickly that a new vaccine must be specially formulated each year. But a relatively new strategy, targeting a rarely seen portion of the virus, is now showing some success.
A novel vaccine developed by microbiologist Peter Palese and collaborators at Mount Sinai School of Medicine in New York showed protective effects in rodents against three different flu strains, with protection ranging from mild (against hemagglutinin 1, such as that of the H1N1 or "swine" flu) to middling (against the avian flu H5 subtype) to absolute (against the common H3 flu subtype). While the results are far from perfect, the proof-of-principle demonstrates the potential for a universal flu vaccine.
- CEO Exchange: Preparing for Population Health
- Advocate, NorthShore Deal Would Create 16-Hospital System
- Better HCAHPS Scores Protect Revenue
- Narrow Networks Cut Costs, Not Quality, Economists Say
- 3 Strategies for Retaining Millennial Employees
- Power of price: In South FL and the nation, healthcare costs often are shrouded in secrecy
- Two NY hospitals to offer free hip and knee replacement surgeries for qualifying patients in December
- Hospital mergers may lead to higher prices
- Healthcare data of 1 million NJ patients compromised since 2009
- CEO Exchange: Pressure is On to Partner, Drive Quality